Drugmakers “not believable?” Why would anyone be surprised?

When you have a clear conflict of interests, you have to work 20 times as hard if you want to be believable! But rather than seeking transparency and fostering trust, all too many pharmaceutical companies have continued to conduct “business as usual.”
A European Commission study has now found that healthcare professionals and payers are “mostly [...]

“Differential pricing” in emerging markets: Part II

Apparently someone in the major media has finally picked up on the strategic initiatives evolving at at least a couple of the major pharmaceutical companies to use differential pricing strategies and focused marketing teams to penetrate the emerging pharmaceutical markets from China, India, and Indonesia to Columbia, Panama, and Brazil. We first blogged about this [...]

In some cases, timing is everything …

IMS Health (a client of Vox Medica) traditionally issued their gobal oncology forecast each October and achieved limited media coverage. This year, they have done something different.

Health care and Web 2.0: now available at …

There’s a lot chatter from the gurus about the potential roles of web 2.0 in building health care “communities of interest.” However, chatter is one thing and actually doing it is another.
If you want to see how this sort of thing actually can work, have a look at the following two linked sites:

The “New” Prostate [...]

Finally … an insider who will talk about (one of) the elephants in the room

According to Mike Huckman of CNBC, a major pharmaceutical industry insider has finally acknowldeged that, “The industry has a black eye.” The problem is that it’s someone whose credibility was at its height nearly 20 years ago, and who knows whether the industry can really “hear him” today.